Physician profile
Christopher M Compton
NPI 1174567176
$17,921.34
in general payments reported to CMS, 2019-2025
53 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $742 · 2021: $1,592 · 2022: $2,246 · 2023: $2,103 · 2024: $8,901 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,400 · Food and Beverage: $5,087 · Travel and Lodging: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,400.00 |
| Food and Beverage | $5,087.24 |
| Travel and Lodging | $285.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $6,685.93 | 2024 | |
| Abbvie INC. | $3,259.24 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $917.86 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $617.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $466.98 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $449.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $444.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $432.92 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.44 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Allergan, INC. | $381.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $334.36 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $306.49 | 2019-2021 | |
| Glaxosmithkline, LLC. | $298.09 | 2019-2024 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $237.32 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $224.22 | 2021-2024 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.